



Versartis
Investor Relations Department
4200 Bohannon Drive
Suite 250
Menlo Park, CA 94025
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: VSAR

Last Trade:	2.13
Trade Time:	4:00 PM ET Dec 11, 2017
Change:	-0.13 (-5.556%)
Day Range	2.10 - 2.30
52-Week Range	1.60 - 24.00
Volume	1,304,276

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.


Company Profile

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry.

Somavaratan (VRS-317) is an investigational, novel, long-acting form of recombinant human growth hormone (rhGH) initially in development for the treatment of GHD in children and adults.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 26, 2017*
[Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- Oct 26, 2017*
[Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions](#)
- Sep 21, 2017*
[Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint](#)
- Sep 7, 2017*
[Versartis' Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentations at IMPE 2017](#)
- Sep 5, 2017*
[Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 10, 2017*
[Annual Report \(10-K\)](#)
- Aug 14, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)